Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

Официальное название

Proton Total Marrow Irradiation-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Обзор

This is an open-label, single-center, non-randomized phase I/II pilot study evaluating proton-based Total Marrow Irradiation (TMI) as part of the conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult patients with high-risk or relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). These patients have an unfavorable prognosis with standard conditioning approaches. Participants will receive a standard conditioning regimen consisting of either myeloablative or reduced-intensity chemotherapy, selected according to age and comorbidities, combined with proton TMI delivered at a total dose of 12 Gy in three fractions. Graft-versus-host disease (GvHD) prophylaxis will be administered according to institutional standards, preferentially using post-transplant cyclophosphamide. Patients will subsequently undergo standard allo-HSCT and will be followed for at least 24 months after transplantation. The primary objective of the study is to assess the safety and tolerability of proton TMI added to standard conditioning, as measured by non-relapse mortality and treatment-related toxicity within the first 100 days after transplantation. Secondary objectives include evaluation of engraftment kinetics, incidence of relapse, overall and relapse-free survival, GvHD outcomes, and quality of life. Study outcomes will be analyzed descriptively and compared with a matched historical cohort.

Подробное описание

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a potentially curative treatment for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, outcomes in patients with high-risk, relapsed, or refractory disease remain poor, largely due to a high incidence of post-transplant relapse and treatment-related toxicity. Attempts to intensify standard conditioning regimens, including escalation of total body irradiation (TBI) doses, have been associated with increased non-relapse mortality (NRM), limiting their clinical applicability.

Total Marrow Irradiation (TMI) is an advanced form of targeted radiotherapy that selectively irradiates the bone marrow while reducing radiation exposure to surrounding organs at risk. Using intensity-modulated planning techniques, TMI enables improved dose conformity compared with conventional TBI. Proton-based TMI may further enhance organ sparing due to the favorable physical dose distribution of protons, potentially reducing both acute and late toxicities while maintaining or increasing antileukemic efficacy.

This study is an open-label, single-center, non-randomized phase I/II pilot trial designed to evaluate proton-based TMI as part of the conditioning regimen prior to allo-HSCT in adult patients with high-risk AML or MDS. Eligible patients include those with relapsed or refractory AML, high-risk AML in complete remission as defined by adverse genetic or molecular features or measurable residual disease, and patients with high-risk or very high-risk MDS according to IPSS-M criteria. All patients must be considered eligible for allo-HSCT based on institutional standards.

Participants will receive one of two conditioning regimens selected according to age, performance status, and comorbidities: a myeloablative regimen consisting of fludarabine, busulfan, and post-transplant cyclophosphamide, or a reduced-intensity regimen consisting of fludarabine, melphalan, and post-transplant cyclophosphamide. In both regimens, proton TMI will be administered at a total dose of 12 Gy (cobalt gray equivalent) delivered in three daily fractions of 4 Gy prior to transplantation. In selected cases with extramedullary disease or central nervous system involvement, additional site-specific irradiation may be incorporated according to protocol-defined rules.

All patients will undergo standard allo-HSCT on day 0 following completion of conditioning. Graft-versus-host disease (GvHD) prophylaxis will be administered according to institutional practice, preferentially using post-transplant cyclophosphamide, with anti-thymocyte globulin permitted in patients at increased risk of cardiotoxicity. Supportive care, infection prophylaxis, and management of transplant-related complications will follow established institutional guidelines.

Patients will be monitored closely during hospitalization and subsequently followed in the outpatient setting. Safety assessments will include systematic recording of adverse events and serious adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Non-relapse mortality will be assessed with relapse treated as a competing risk. Acute and chronic GvHD will be evaluated using established international criteria. Follow-up visits are scheduled through day 100 and at months 6, 12, and 24 after transplantation, with assessments of engraftment, organ function, disease status, survival, and quality of life.

The primary objective of the study is to assess the safety and tolerability of proton-based TMI added to standard conditioning, as measured by non-relapse mortality and treatment-related toxicity within the first 100 days after transplantation. Secondary objectives include evaluation of engraftment kinetics and graft failure, cumulative incidence of relapse, overall survival, relapse-free survival, GvHD-free/relapse-free survival, incidence of acute and chronic GvHD, and patient-reported quality of life.

Given the pilot nature of the study and the limited sample size, outcomes will be analyzed descriptively. Where appropriate, results will be compared with a matched historical cohort of patients treated at the same institution using propensity score matching and Bayesian power prior methodology. The findings of this study are intended to inform the feasibility, safety, and future development of proton-based TMI as a conditioning strategy for high-risk AML and MDS.

Вмешательства

• Лучевая терапия Proton Total Marrow Irradiation
  Proton total marrow irradiation (TMI) is administered as part of the conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. TMI is delivered to a total dose of 12 cobalt gray equivalents (CGE) in 3 fractions of 4 CGE once daily. In patients with extramedullary disease or central nervous system involvement, additional site-specific irradiation may be administered prior to TMI (10 CGE in 5 fractions), with a simultaneous integrated boost to involved sites during TMI (3 f

Первичные конечные точки

• Incidence of adverse events (AEs) and serious adverse events (SAEs) [Срок оценки: Up to 100 days post-transplantation]
• Non-relapse mortality (NRM) [Срок оценки: Up to 100 days post-transplantation]

Вторичные конечные точки (12)

• Cumulative incidence of neutrophil engraftment [Срок оценки: Up to 100 days post-transplantation]
• Cumulative incidence of platelet engraftment [Срок оценки: Up to 100 days post-transplantation]
• Transfusion independence [Срок оценки: Up to 100 days post-transplantation]
• Incidence of primary graft failure [Срок оценки: Up to 100 days post-transplantation]
• Cumulative incidence of relapse at 12 months [Срок оценки: 12 months post-transplantation]
• Cumulative incidence of relapse at 24 months [Срок оценки: 24 months post-transplantation]
• Relapse-Free Survival (RFS) at 12 months [Срок оценки: 12 months post-transplantation]
• Relapse-Free Survival (RFS) at 24 months [Срок оценки: 24 months post-transplantation]
• Overall Survival (OS) at 12 months [Срок оценки: 12 months post-transplantation]
• Overall Survival (OS) at 24 months [Срок оценки: 24 months post-transplantation]
• GVHD-Free, Relapse-Free Survival (GRFS) at 12 months [Срок оценки: 12 months post-transplantation]
• GVHD-Free, Relapse-Free Survival (GRFS) at 24 months [Срок оценки: 24 months post transplantation]

Критерии участия

Критерии включения

• Underlying diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS),

A) Acute Myeloid Leukemia (AML), meeting at least one of the following criteria:

i. Relapsed disease after a prior complete remission (CR) or

ii. Disease refractory to at least two cycles of intensive chemotherapy or

iii. High-risk AML in complete remission (CR), defined by at least one of the following:

iii a) Adverse molecular or cytogenetic risk according to ELN 2022 classification or

iii b) Presence of measurable/minimal residual disease (MRD).

B) Myelodysplastic Syndrome (MDS), meeting at least one of the following criteria:

i. Relapsed MDS with increased blasts (MDS-IB) or

ii. MDS-IB2 without reduction of bone marrow blasts below 10% after induction chemotherapy or after at least two cycles of azacitidine or

iii. IPSS-M score > 0.5 (high-risk or very high-risk disease).

• Eligibility confirmed by the institutionalal Transplant Indication Committee according to standard criteria.
• Age ≥ 18 years and ≤ 65 years
• Ability to understand and voluntarily sign written informed consent

Критерии исключения

Severe comorbidity, defined as the presence of one or more of the following conditions:

• Left ventricular ejection fraction (LVEF) < 40%
• Creatinine clearance < 0.5 mL/s
• Total bilirubin > 40 µmol/L (unless attributable to Gilbert's syndrome or hemolysis) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 × upper limit of normal (ULN)
• Pulmonary function impairment defined as forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) < 50% of predicted value, or diffusing capacity of the lung for carbon monoxide (DLCO) < 50% of predicted value after correction for anemia
• Karnofsky Performance Status < 70%
• Active viral hepatitis or human immunodeficiency virus (HIV) infection
• Presence of liver cirrhosis
• Pregnancy

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Чехия · 2 центра

• Institute of Hematology and Blood Transfusion — Prague
• Proton Therapy Center Czech — Prague

Публикации

• The EBMT Handbook Textbook Open Access 2024
• Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in c PMID 16338616
• Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wolfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report f PMID 26386318
• Corvo R, Zeverino M, Vagge S, Agostinelli S, Barra S, Taccini G, Van Lint MT, Frassoni F, Bacigalupo A. Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant. Radiother Oncol. 2011 Mar;98(3):382-6. doi: 10.1016/j.radonc.2011.01.016. Epub 2011 Feb 19. PMID 21339008
• Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010 Aug 10;28(23):3730-8. doi: 10.1200/JCO.2010.28.8852. Epub 2010 Jul 1 PMID 20625136
• Dominietto A, Vagge S, di Grazia C, Bregante S, Raiola AM, Varaldo R, Gualandi F, Gusinu M, Barra S, Agostinelli S, Angelucci E, Hui S. Total Marrow Irradiation for Second Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia. Transplant Cell Ther. 2023 Aug;29(8):506.e1-506.e6. doi: 10.1016/j.jtct.2023.04.014. Epub 2023 Apr 23. PMID 37094701
• Taccone A, Oddone M, Dell'Acqua AD, Occhi M, Ciccone MA. MRI "road-map" of normal age-related bone marrow. II. Thorax, pelvis and extremities. Pediatr Radiol. 1995;25(8):596-606. doi: 10.1007/BF02011826. PMID 8570312
• Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients PMID 28087456

Идентификаторы

NCT: NCT07532824 · UHKT-PTC-TMI-01

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗